Skip to content

mbeck

NMIN research leader’s finding selected as journal’s feature article

Research by NMIN research leader Dr. Marcel Bally and team at Cuprous Pharmaceuticals is featured on the cover of the February 2020 issue of Drug Delivery and Translational Research. The article, Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use, discusses the benefits brought to quercetin by Cuprous’ Metaplex… Read More »NMIN research leader’s finding selected as journal’s feature article

“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology

On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR). The approval of ONPATTRO™ has opened the door to a new era of gene therapies to treat most human diseases—including… Read More »“A new era of medicine:” NMIN thought leaders in Nature Nanotechnology

NMIN holds its first Scientific Meeting

Over 100 delegates—researchers, trainees, partner organization representatives and other stakeholders—gathered at the Sheraton Vancouver Wall Centre in Vancouver, British Columbia, on September 13-14, 2019, to take part in NMIN’s first Scientific Meeting. Previous Next Read about the event in NMIN’s November 2019 Newsletter. See the Event Program for the full agenda, speakers’… Read More »NMIN holds its first Scientific Meeting

NMIN receives funding from NCE Program

UBC attracts over $40M to host Networks of Centres of Excellence in nanomedicines Apr 16, 2019 – The NanoMedicines Innovation Network (NMIN) has been awarded $18.5 million in new funding from the Networks of Centres of Excellence (NCE), a federal program that connects teams of scientists across Canada to collaborate… Read More »NMIN receives funding from NCE Program